Details

Autor(en) / Beteiligte

• Nechifor-Boilă, Ioan Alin
• Loghin, Andrada
• Nechifor-Boilă, Adela
• Decaussin-Petrucci, Myriam
• Voidăzan, Septimiu
• Chibelean, Bogdan Călin
• Martha, Orsolya
• Borda, Angela

Titel

PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy

Ist Teil von

• Life (Basel, Switzerland), 2021-04, Vol.11 (5), p.404

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2021

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• In the present study, we analyzed Programmed Death Ligand-1 (PD-L1) expression in radical cystectomy (RC) specimens from patients with muscle-invasive urothelial carcinoma (UC), in order to assess any correlations with specific clinicopathological features and its potential prognostic value. A multi-institutional study was performed within the departments of urology and pathology at the Mureș County Hospital, Romania, and Centre Hospitalier Lyon Sud, France. Sixty-nine patients with MIBC were included, for whom tumor histology (conventional versus histological variant/differentiation), tumor extension (T), lymph node involvement (N), and distant metastases (M) were recorded. PD-L1 immunostaining was performed using the 22C3 clone and was interpreted using the combined positive score (CPS) as recommended (Dako Agilent, Santa Clara, CA, USA). Positive PD-L1 immunostaining was more prevalent among UCs with squamous differentiation compared to conventional UCs and trended towards an improved OS ( = 0.366). We found the T stage to be a risk factor for poor survival in PD-L1-positive patients (HR 2.9, = 0.021), along with the N stage in PD-L1-negative patients (HR 1.98, = 0.007). No other clinicopathological factor was found to be significantly associated with PD-L1 positivity. Thus, we confirm the need for PD-L1 immunostaining prior to initiating immune checkpoint inhibitor therapy for a more accurate assessment of the patients' chances of responding to treatment.